spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  autism 

 HSMN NewsFeed - 8 Nov 2022
Sensorium Therapeutics Closes $30 Million Series A to Transform Mental Health Treatment with Nature-Inspired Psychoactive Medicines
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 May 2022
MindMed Appoints Schond L. Greenway as Chief Financial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 4 Apr 2022
FDA approves Nobelpharma's HYFTOR(TM) (sirolimus topical gel) 0.2%
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2022
Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders
Diagnostics Product Launch
 HSMN NewsFeed - 27 Jan 2022
SciSparc Presents New Leadership Lineup
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 30 Mar 2021
Biom Therapeutics Receives Orphan Drug Status for BIO017 from the U.S. FDA for the treatment of Angelman Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 28 May 2019
True Diagnostics, Inc. Receives FDA 510(k) Clearance to Market VeriClear(TM) Digital Test Device for Early Result Pregnancy
Diagnostics FDA
 HSMN NewsFeed - 11 Dec 2018
GenEdit Closes $8.5 million Series Seed Financing
Regenerative Medicine Venture Capital Personnel
 HSMN NewsFeed - 22 Feb 2018
Kallyope Inc. Announces $66M Series B Financing to Advance Programs Targeting the Gut-Brain Axis
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 22 Jan 2018
AVACEN Medical Device for Autistic Spectrum Disorder Behavior Management Launched in Hong Kong
Devices Product Launch
 HSMN NewsFeed - 1 Dec 2017
Elekta Introduces New Commercial Name for MEG Business and Reveals New System for Studying Brain Activity at 2017 American Epilepsy Society Meeting
Devices Radiology Neurology Product Launch
 HSMN NewsFeed - 30 May 2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 31 Mar 2017
Vencerx Therapeutics Announces Appointments of Robert H. Ring, Ph.D. as Chief Executive Officer and Jeffrey Stevenson as Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 3 Jan 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Dec 2016
Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS(TM) (Ocrelizumab) Published in New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Nov 2016
Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (PedPRM) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD)
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Apr 2016
Joseph Horrigan Joins AMO Pharma as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2016
Lumos Pharma Appoints David M. Weiner, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Feb 2016
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 Oct 2015
Jzaneen Lalani Joins Curemark as Chief Operating Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 6 Oct 2015
OptiNose Closes New Round of Financing
Devices Drug Delivery Venture Capital
 HSMN NewsFeed - 30 Jun 2015
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 May 2014
Retrophin Names Stephen Aselage President and Chief Operations Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2013
Coronado Biosciences Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2013
Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
Diagnostics Personalized Medicine Venture Capital
 HSMN NewsFeed - 12 Dec 2013
Retrophin Announces Agreement to Acquire Kyalin Biosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 14 Oct 2013
IntegraGen Obtains Exclusive License for MicroRNA Which Predicts Therapy Outcomes in Metastatic Colorectal Cancer
Diagnostics Oncology Licensing
 HSMN NewsFeed - 7 Oct 2013
Kevin Hrusovsky Joins SynapDx Board of Directors
Diagnostics Neurology Venture Capital
 HSMN NewsFeed - 24 Apr 2013
Coronado Biosciences Announces Departure of Dr. Bobby W. Sandage, Jr.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2012
Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 23 Mar 2011
Asuragen Launches CE Marked IVD AmplideX(TM) Fragile X Test in Europe
Diagnostics Regulatory
 HSMN NewsFeed - 21 Dec 2010
Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 Oct 2010
Omeros Receives $20 Million from Vulcan Capital and $5 Million Grant Award from Washington State's Life Sciences Discovery Fund to Advance its GPCR Program
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Oct 2010
Cortex Obtains Exclusive Worldwide Rights for the Combination of AMPAKINE(R) and mGluR5 Compounds for the Treatment of Fragile X
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 7 Sep 2010
James F. Szigethy Named Curemark's Director of New Product Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 20 Jul 2010
Seaside Therapeutics Appoints Leading Industry Executives to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2010
SynapDx Corporation Raises $9 Million in Series A Funding
Diagnostics Venture Capital
 HSMN NewsFeed - 13 Apr 2010
Entest Biomedical Announces Intent to Acquire Medistem
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 9 Mar 2010
Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology
Devices Neurology
 HSMN NewsFeed - 8 Mar 2010
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2010
MicroTransponder Raises $10 Million to Begin Clinical Trials of Wireless Neurostimulation for Chronic Pain and Obtain FDA Clearance
Devices Venture Capital Personnel
 HSMN NewsFeed - 13 Jan 2010
Population Diagnostics, Inc. Appoints Dr. Peggy Eis as Chief Technology Officer
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 17 Sep 2009
Seaside Therapeutics Secures $30 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Feb 2009
CHMP delays European Commission decision process to approve ZEVTERA(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Dec 2008
Leading European Universities Choose Elekta to Deliver Advanced 3D Brain Mapping Tool for Research
Devices Neurology
 HSMN NewsFeed - 24 Apr 2008
Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Jan 2008
Nastech Appoints Bruce R. York as Interim Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2007
Nastech Announces Promotion of Gordon Brandt, M.D. to President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Nov 2007
Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2007
Elekta: Finding Hope for Autism - New Brain Research Technology Centre Opened by HRH Princess Anne
Devices Neurology
 HSMN NewsFeed - 4 Oct 2007
Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
Biopharmaceuticals Personnel Drug Delivery
 HSMN NewsFeed - 1 Oct 2007
Oralflo Helps the Medicine Go Down
Devices
 HSMN NewsFeed - 30 Aug 2007
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2007
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2007
Alexian Brothers Hospital Network To Bring Advanced Brain Mapping Technology To Chicagoland
Devices Neurology
 HSMN NewsFeed - 1 Mar 2007
FDA Grants Pediatric Exclusivity for RISPERDAL(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Aug 2006
Seaside Therapeutics Announces Key Leadership Appointment of Dr. Timothy D. Ocain to the Position of Senior Vice President, Research & Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Aug 2006
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2006
IntegraGen Appoints Jorg Leenings as Head of Sales and Marketing of its German Competence Centre for Genetic Diabetes Testing
Diagnostics Personnel
 HSMN NewsFeed - 31 Mar 2006
Prestwick Pharmaceuticals Receives FDA Approvable Letter for XENAZINE(R) (Tetrabenazine) for Treatment of Chorea Associated with Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 Feb 2006
Study Published in Neurology Shows Tetrabenazine Significantly Improves Debilitating Movement Disorder Caused by Huntington's Disease
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
autism
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.